Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on September 20, 2017. The report details the entry into a material definitive agreement involving the issuance of debt and equity instruments to an accredited investor.
Key Financial Metrics and Transaction Details
- Debt Issuance: A convertible promissory note with a principal amount of $150,000.
- Interest Rate: 6% per annum, payable in arrears on the Maturity Date.
- Warrant Issuance: A seven-year warrant to purchase 60,000 shares of common stock.
- Warrant Exercise Price: $5.90 per share.
- Maturity Date: The earlier of the 5-year anniversary of issuance or the date of a "Qualified Financing" (aggregate proceeds of at least $2,000,000).
- Liquidity Impact: The filing does not provide specific cash flow or liquidity metrics beyond the principal amount raised.
Material Changes and Terms
The filing reports a new financial obligation and potential equity dilution. Key terms include:
- Conversion Mechanics: Upon maturity or a Qualified Financing, the investor may convert the note into common stock or Series C Convertible Preferred Stock at a price equal to the lesser of 80% of the Qualified Financing price (or estimated value) or $5.90 per share.
- Letter Agreement: A separate agreement stipulates that if a Qualified Financing occurs prior to December 31, 2017, resulting in a listing on NYSE American or Nasdaq, the note will automatically convert at the same discount terms.
- Ownership Cap: The warrant holder cannot exercise if it would result in beneficial ownership exceeding 9.99% of outstanding common stock, unless the cap is adjusted with 61 days' notice.
Guidance, Risks, and Unusual Items
- Unregistered Sales: The securities were issued pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, exempting them from registration requirements.
- Transfer Restrictions: Under the Letter Agreement, the investor agreed not to transfer or sell securities received upon conversion in a Qualified Financing, subject to exceptions.
- Change of Control: In the event of a change of control, the investor has the option to receive cash or convert the note at a discounted price based on the implied value of the transaction.
Investor Verification Checklist
- Verify the company name is NanoVibronix, Inc., not Envue Medical, Inc.
- Confirm the total capital raised ($150,000) relative to the company's current cash position and burn rate.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific anti-dilution provisions and conversion triggers.
- Assess the likelihood of a "Qualified Financing" occurring before December 31, 2017, which would trigger automatic conversion.
- Monitor the impact of the 9.99% beneficial ownership limitation on the warrant's exercisability.